Financials in USD. Standardized financial statements.
A compact view of how Beijing Tong Ren Tang Chinese Medicine Company Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.51B | $12.52B | $1.53B | $1.73B | $1.56B | $1.32B | $1.44B | $1.51B | $1.26B | $1.08B |
| Revenue Growth? | -87.9% | +720.9% | -11.8% | +11.1% | +18.3% | -8.5% | -5.0% | +19.8% | +16.5% | 0.0% |
| Cost of Revenue? | $587.65M | $546.32M | $477.73M | $644.36M | $444.60M | $374.55M | $433.43M | $453.90M | $367.00M | $304.55M |
| Gross Profit? | $925.36M | $1.07B | $1.05B | $1.15B | $1.11B | $952.90M | $1.00B | $1.06B | $896.97M | $780.12M |
| Gross Margin? | +61.2% | +8.5% | +68.7% | +66.5% | +71.4% | +72.5% | +69.9% | +70.0% | +71.0% | +71.9% |
| Operating Expenses? | $451.89M | $491.44M | $423.12M | $338.44M | $340.91M | $283.50M | $353.39M | $364.08M | $295.80M | $256.32M |
| Operating Income? | $473.47M | $573.89M | $624.18M | $811.27M | $770.41M | $669.44M | $650.97M | $696.06M | $597.68M | $527.50M |
| EBITDA? | $571.81M | $722.00M | $640.61M | $876.38M | $786.57M | $769.04M | $777.43M | $751.30M | $627.73M | $547.44M |
| Income Before Tax | $504.57M | $627.44M | $687.80M | $826.52M | $778.01M | $686.67M | $689.22M | $720.98M | $609.99M | $534.27M |
| Income Tax Expense | $87.81M | $100.56M | $97.18M | $134.51M | $126.83M | $118.00M | $112.77M | $119.59M | $105.29M | $92.42M |
| Net Income? | $397.12M | $500.05M | $4.22B | $645.11M | $607.75M | $542.39M | $558.12M | $580.78M | $489.19M | $420.46M |
| EPS? | $0.47 | $4.66 | $0.65 | $0.77 | $0.73 | $0.65 | $0.67 | $0.69 | $0.58 | $0.50 |
| Diluted EPS? | $0.47 | $4.66 | $0.65 | $0.77 | $0.73 | $0.65 | $0.67 | $0.69 | $0.58 | $0.50 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality